Daiichi Sankyo Co Ltd
4568.T- Latest Trade
- trading higher3,277JPY
- Change
- 0
- % Change
0.00%
- Day Range
- -- - --
- 52-Week Range
- 1,981.00 - 3,456.00
As of May 19 2022. Values delayed up to 15 minutes
- Previous Close
- 3,277.00
- Open
- 0.00
- Volume
- 0.00
- 3 Month Average Trading Volume
- 99.26
- Shares Out (Mil)
- 1,916.79
- Market Cap
- 6,380,431.00
- Forward P/E
- 74.50
- Dividend Yield
- 0.82
Key Statistics
1.86666667 mean rating - 15 analysts
- P/E Excl. Extra Items (TTM)
- 93.90
- Price To Sales (TTM)
- 6.11
- Price To Book (Quarterly)
- 4.65
- Price To Cash Flow (Per Share TTM)
- 50.95
- Total Debt/Total Equity (Quarterly)
- 12.10
- Long Term Debt/Equity (Quarterly)
- 10.59
- Return On Investment (TTM)
- 3.76
- Return On Equity (TTM)
- 3.11
2021 (millions USD)
About Daiichi Sankyo Co Ltd
Company Information
Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.
Address
Daiichi Sankyo Bldg. A/B Kan 3-5-1, Nihombashi Hon-choCHUO-KU, TKY
103-8426
Japan
Industry
Biotechnology & Drugs
Executive Leadership
- Sunao Manabe
- Executive President, President, Chief Executive Officer, Representative Director
- Hiroyuki Okuzawa
- Chief Financial Officer, Managing Executive Officer, Chief Director of Business Planning & Administration, Director
- Kentaro Takamura
- Managing Executive Officer, Director of Finance & Accounting in Main Business Planning & Administration Unit
- Masahiko Ohtsuki
- Chief Information Officer, Senior Managing Executive Officer, Chief Director of DX Promotion, Director
- Shoji Hirashima
- Senior Managing Executive Officer, Chief Director Business Strategy, Director
- Satoru Kimura
- Senior Managing Executive Officer, Manager of Japan Business Unit, Representative Director
- Junichi Fukute
- Managing Executive Officer, Chief Director of Supply Chain
- Hironobu Furuta
- Managing Executive Officer, CISO, Chief Director of General Affairs
- Wataru Takasaki
- Managing Executive Officer, Chief Director of Research & Development
- Masayuki Yabuta
- Managing Executive Officer, Chief Director of Biologics
- Akio Sakurai
- Executive Officer, Chief Director of Sales in Japan Business Unit
- Yoshinori Kaneshima
- Executive Officer, Chief Director of Marketing in Japan Business Unit
- Toshinori Agatsuma
- Executive Officer, Director of Oncology 1st Research Institute in Research Supervision Unit in Main Research & Development Unit
- Miyuki Arai
- Executive Officer, Chief Director of Reliability Assurance
- Takashi Fukuoka
- Executive Officer
- Tomoji Hashiba
- Executive Officer
- Hideyuki Hirano
- Executive Officer, Director of Business Administration in Japan Business Unit
- Hiroto Kashiwase
- Executive Officer, Chief Director of Pharmaceutical Technology
- Seiichiro Kumakura
- Executive Officer, Senior Director of Translational Medicine in Main Research & Development Unit
- Takashi Matsumoto
- Executive Officer
- Nobuo Murakami
- Executive Officer, Director of Business Strategy in Main Business Strategy Unit
- Kiminori Nagao
- Executive Officer, President of ASCA Company
- Koji Ogawa
- Executive Officer
- Hironobu Saito
- Executive Officer, Chief Director of Medical Affairs in Japan Business Unit
- Toru Takahashi
- Executive Officer, Senior Director of Research in Main Research & Development Unit
- Naoto Tsukaguchi
- Executive Officer, Director of Legal Affairs in Main General Affairs Unit
- Tsuguya Fukui
- Independent Director
- Kazuaki Kama
- Independent Director
- Sawako Nohara
- Independent Director
- Noritaka Uji
- Independent Director
Latest News
- MarketsJapan's Nikkei ends lower for fourth day as Ukraine crisis worsens
Japan's Nikkei index slumped to a fourth day of losses on Tuesday, as sentiment soured further after an escalation in tensions around Ukraine.
- MarketsNikkei tumbles over 2% as deepening Ukraine crisis weighs
Japan's Nikkei share average tumbled more than 2% on Tuesday, extending losses to a fourth session, as sentiment soured further following an escalation in tensions around Ukraine.
- MarketsJapanese shares edge higher as gains in Toyota, Sony offset tech losses
Japanese shares inched up on Wednesday, as gains in Toyota Motor and Sony Group were offset by weak performance of technology heavyweights and a sell-off in expensive growth stocks driven by rising U.S. Treasury yields.
- MarketsNikkei ends 2% higher on bargain-buying, led by tech shares
Japanese equities closed sharply higher on Tuesday, with tech heavyweights leading the rebound from a two-day decline, as investors snapped up stocks sold off on concerns about the Omicron COVID-19 variant.
- MarketsJapanese shares jump on bargain hunting, chip sector shines
Japanese equities jumped on Tuesday after two sessions of decline, with chip-related Tokyo Electron and Advantest leading the pack, as investors snapped up stocks that were dragged by concerns of the Omicron COVID-19 variant.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,812.20 | 0.20%Negative |
| Copper | 770.50 | 1.87%Positive |
| Brent Crude Oil | 111.58 | 2.26%Positive |
| CBOT Soybeans | 1,690.75 | 1.68%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,900.79 | 0.58%Negative |
| Euro STOXX 50 | 3,640.55 | 1.36%Negative |
| FTSE 100 | 7,302.74 | 1.82%Negative |
| Nikkei 225 | 26,402.84 | 1.89%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes